Evidence map›Paper›PMID 31530833›Full record

ArticleScientific reports2019

Pharmacological inhibition of Notch signaling regresses pre-established abdominal aortic aneurysm.

Neekun Sharma, Rishabh Dev, Juan de Dios Ruiz-Rosado, Santiago Partida-Sanchez, Mireia Guerau-de-Arellano, Pramod Dhakal, Helena Kuivaniemi, Chetan P Hans

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Lack of endothelial estrogen receptor alpha signaling exacerbates abdominal aortic aneurysm in male mice.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  2. Review
  3. The Role of NADAmerican journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Neekun SharmaDepartment of Cardiovascular Medicine, University of Missouri, Columbia, USA.
Rishabh DevDepartment of Cardiovascular Medicine, University of Missouri, Columbia, USA.
Juan de Dios Ruiz-RosadoCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Santiago Partida-SanchezCenter for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-2996-9440
Mireia Guerau-de-ArellanoSchool of Health and Rehabilitation Sciences, Medical Laboratory Science Division, The Ohio State University, Columbus, OH, USA.
Pramod DhakalAnimal Science Research Center, University of Missouri, Columbia, USA.
Helena KuivaniemiDivision of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-5753-8766
Chetan P HansDepartment of Cardiovascular Medicine, University of Missouri, Columbia, USA. HansCP@health.missouri.edu.ORCID http://orcid.org/0000-0003-1830-9084
University of Missouri · USNationwide Children's Hospital · USStellenbosch University · ZAThe Ohio State University · USUniversity of Missouri Health System · US

Funding

Epigenetic modulation of T cell tolerance in Multiple Sclerosis autoimmunityR01AI121405 · NIAID · OHIO STATE UNIVERSITY · PI GUERAU-DE-ARELLANO, MIREIA · 2016 to 2020
$2.2M
Role of Notch1 Signaling in Abdominal Aortic AneurysmR01HL124155 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI HANS, CHETAN · 2015 to 2019
$1.9M
Novel Epigenetic Modifier Inhibitor Drugs for T cell Modulation in Multiple SclerosisR21AI127354 · NIAID · OHIO STATE UNIVERSITY · PI GUERAU-DE-ARELLANO, MIREIA · 2017 to 2018
$404k
NHLBI NIH HHS R01 HL124155NIAID NIH HHS R01 AI121405NIAID NIH HHS R21 AI127354
6 · The paper itself

Abstract

Abdominal aortic aneurysm (AAA) is characterized by transmural infiltration of myeloid cells at the vascular injury site. Previously, we reported preventive effects of Notch deficiency on the development of AAA by reduction of infiltrating myeloid cells. In this study, we examined if Notch inhibition attenuates the progression of pre-established AAA and potential implications. Pharmacological Notch inhibitor (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester; DAPT) was administered subcutaneously three times a week starting at day 28 of angiotensin II (AngII) infusion. Progressive increase in pulse wave velocity (PWV), maximal intra-luminal diameter (MILD) and maximal external aortic diameter (MEAD) were observed at day 56 of the AngII. DAPT prevented such increase in MILD, PWV and MEAD (P < 0.01). Histologically, the aortae of DAPT-treated Apoe

Indexed as

ADP-ribosyl Cyclase 1Angiotensin IIAnimalsAortaAortic Aneurysm, AbdominalCells, CulturedCollagenCytokinesDipeptidesDisease Models, AnimalExtracellular MatrixGene Expression RegulationHumansMaleMembrane GlycoproteinsMiceADP-ribosyl Cyclase 1Angiotensin IICD38 protein, humanCollagenCytokinesDipeptidesMembrane GlycoproteinsN-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl esterReceptors, Notch

Identifiers

PMID31530833
PMCPMC6748927
OpenAlexW2974649943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.